日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.

通过胞吞途径转换和干扰素反应抑制增强工程化细胞外囊泡的抗肿瘤作用。

Huang Zixuan, Lu Chaoqun, Wang Yixin, Xian Huajian, Zheng Yuling, Kang Ting, Xiang Rufang, Xie Shufeng, Wang Minghui, Li Zeyi, Xia Xiaoli, Yu Yaoyifu, Zhang Wenjie, Zheng Huijian, Pan Renyao, Li Dan, Zhao Chunjun, Liu Han

The nuclear factor-κ B inhibitor SN50 enhances the efficacy of B-cell maturation antigen-targeted chimeric antigen receptor T-cell therapy

核因子-κB抑制剂SN50可增强靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法的疗效

Long, Jinlan; Xie, Shufeng; Zhang, Wenjie; Dou, Weiyu; Wang, Yixin; Wang, Ruiheng; Liu, Han; Xu, Zhenshu

Establishment of a prognostic model based on ER stress-related cell death genes and proposing a novel combination therapy in acute myeloid leukemia.

建立基于内质网应激相关细胞死亡基因的预后模型,并提出急性髓系白血病的新联合治疗方案

Wang Minghui, Xian Huajian, Xia Xiaoli, Zhang Wenjie, Huang Zixuan, Lu Chaoqun, Zheng Yuling, Wang Yixin, Xie Shufeng, Pan Renyao, Yu YaoYifu, Wang Ruiheng, Zheng Huijian, Huang Guorui, Liu Han

Novel CAR T-cell therapies for relapsed/refractory B-cell malignancies: latest updates from 2023 ASH annual meeting

针对复发/难治性B细胞恶性肿瘤的新型CAR-T细胞疗法:2023年ASH年会最新进展

Zhang, Wenjie; Li, Sumei; Long, Jinlan; Xie, Shufeng; Wang, Minghui; Liu, Han; Xu, Zhenshu

Correction: Arsenic trioxide and p97 inhibitor synergize against acute myeloid leukemia by targeting nascent polypeptides and activating the ZAKα-JNK pathway

更正:三氧化二砷和p97抑制剂通过靶向新生多肽并激活ZAKα-JNK通路,协同对抗急性髓系白血病。

Xie, Shufeng; Liu, Hui; Zhu, Shouhai; Chen, Zhihong; Wang, Ruiheng; Zhang, Wenjie; Xian, Huajian; Xiang, Rufang; Xia, Xiaoli; Sun, Yong; Long, Jinlan; Wang, Yuanli; Wang, Minghui; Wang, Yixin; Yu, Yaoyifu; Huang, Zixuan; Lu, Chaoqun; Xu, Zhenshu; Liu, Han

A Novel Identified Necroptosis-Related Risk Signature for Prognosis Prediction and Immune Infiltration Indication in Acute Myeloid Leukemia Patients

一种新型的坏死性凋亡相关风险特征在急性髓系白血病患者预后预测和免疫浸润指示中的应用

Sun, Yong; Wang, Ruiheng; Xie, Shufeng; Wang, Yuanli; Liu, Han

miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4

miR-137 通过靶向 DUSP4 抑制上皮-间质转化,减轻乳腺癌对阿霉素的耐药性

Feiya Du, Ling Yu, Ying Wu, Shuqian Wang, Jia Yao, Xiaoxiao Zheng, Shangzhi Xie, Shufeng Zhang, Xuemei Lu, Yu Liu, Wei Chen